Summary:
- Merck's investigational zilovertamab vedotin, in combination with R-CHP, demonstrated a 100% complete response rate at the 1.75 mg/kg dose in a Phase 2 trial for previously untreated patients with diffuse large B-cell lymphoma (DLBCL).
- The trial evaluated the safety and efficacy of zilovertamab vedotin, an antibody-drug conjugate, in combination with the standard chemotherapy regimen R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) in previously untreated DLBCL patients.
- The results show promising activity of the zilovertamab vedotin and R-CHP combination, which could potentially offer a new treatment option for DLBCL patients if the findings are confirmed in further studies.